Medical Research Center, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, People's Republic of China.
The Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, 243 Charles Street, Boston, MA, USA.
Eur Arch Otorhinolaryngol. 2024 Aug;281(8):4191-4199. doi: 10.1007/s00405-024-08695-w. Epub 2024 May 3.
Identifying the biomarkers for uncontrolled chronic rhinosinusitis (CRS) is important for directing treatment decisions. Eosinophilia has been reported to be involved in the poor disease control of CRS and mucus eosinophil-derived neurotoxin (EDN) is potentially a biomarker of intense eosinophil activation. This study aimed to assess the relationship between mucus EDN levels, disease severity, and degree of CRS control.
A total of 150 adult patients with CRS and 25 healthy controls were prospectively enrolled. The nasal mucus and tissue specimens were collected to analyze EDN levels. Disease severity was assessed by Lund-Mackay score and 22-item Sino-Nasal Outcome Test (SNOT-22) score. Five CRS symptom severities during the prior month (nasal blockage, rhinorrhoea/postnasal drip, facial pain/pressure, smell, sleep disturbance or fatigue), use of rescue medications in the last six months, and the presence of diseased mucosa on nasal endoscopy were obtained. Consistent with the European Position Paper on Rhinosinusitis and Nasal Polyps 2020 CRS control criteria, uncontrolled CRS was defined as meeting at least three items.
40% of patients with CRS presented with uncontrolled status. Patients with uncontrolled CRS had significantly higher nasal mucus EDN levels (P = 0.010), percentage of blood eosinophil (P = 0.015), SNOT-22 score (P < 0.001), Lund-Mackay score (P = 0.008), and a more eosinophilic dominant phenotype of CRS (P < 0.001) than patients with controlled CRS. Furthermore, mucus EDN levels were positively correlated with blood eosinophils (r = 0.541, P = 0.005), SNOT-22 score (r = 0.460, P = 0.021), and Lund-Mackay score (r = 0.387, P = 0.039). Mucus EDN levels were the significant parameter related to uncontrolled CRS in multivariable analysis after adjusting for patient demographics and comorbidities (odds ratio = 1.323; P = 0.004).
Mucus EDN levels may be a potential biomarker for identifying the CRS control status.
识别慢性鼻-鼻窦炎(CRS)失控的生物标志物对于指导治疗决策非常重要。嗜酸性粒细胞增多已被报道与 CRS 疾病控制不良有关,而粘液嗜酸性粒细胞衍生神经毒素(EDN)可能是嗜酸性粒细胞强烈激活的生物标志物。本研究旨在评估粘液 EDN 水平与疾病严重程度和 CRS 控制程度之间的关系。
前瞻性纳入 150 例 CRS 成年患者和 25 名健康对照者。采集鼻粘液和组织标本分析 EDN 水平。采用 Lund-Mackay 评分和 22 项鼻-鼻窦炎结局测试(SNOT-22)评分评估疾病严重程度。获取过去一个月内五种 CRS 症状严重程度(鼻塞、流涕/后鼻滴注、面部疼痛/压痛、嗅觉、睡眠障碍或疲劳)、过去六个月内使用急救药物情况以及鼻内镜下存在病变粘膜的情况。根据 2020 年欧洲鼻-鼻窦炎和鼻息肉立场文件,将 CRS 控制不佳定义为符合至少三项标准。
40%的 CRS 患者表现为控制不佳。与 CRS 控制患者相比,控制不佳的 CRS 患者的鼻粘液 EDN 水平显著升高(P=0.010),血嗜酸性粒细胞百分比(P=0.015)、SNOT-22 评分(P<0.001)、Lund-Mackay 评分(P=0.008)和 CRS 嗜酸性粒细胞优势表型更为明显(P<0.001)。此外,粘液 EDN 水平与血嗜酸性粒细胞(r=0.541,P=0.005)、SNOT-22 评分(r=0.460,P=0.021)和 Lund-Mackay 评分(r=0.387,P=0.039)呈正相关。在调整患者人口统计学和合并症后,粘液 EDN 水平是多变量分析中与 CRS 控制不佳相关的显著参数(比值比=1.323;P=0.004)。
粘液 EDN 水平可能是识别 CRS 控制状态的潜在生物标志物。